Boehringer Ingelheim Signs a Research Agreement with Twist to Discover Therapeutic Antibodies Against Multiple Targets
Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research
Shots:
- Twist to receive an up front for each program and $710M in clinical, regulatory, and commercial milestones for the multiple target discovery programs
- Boehringer Ingelheim obtains global exclusive rights to develop and commercialize any therapeutic Ab discovered under the collaboration
- The collaboration will utilize Twist’s Ab libraries that derived from human sequences to discover therapeutic Abs against multiple targets
Click here to read full press release/ article | Ref: | Image: PharmaLive